Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Revatio · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A | ACTIVE_COMPARATOR | Revatio 20 mg intact tablet. This is the reference treatment arm. |
| Treatment B | EXPERIMENTAL | Treatment B: Revatio 20 mg crushed tablet mixed with apple sauce. |
| Treatment C | EXPERIMENTAL | Treatment C: Revatio 20 mg extemporaneously prepared suspension (EP). |
| Name | Type | Description |
|---|---|---|
| Revatio | DRUG | Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject. |
Inclusion Criteria: * Healthy male/female subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and cli...
Revatio is a small molecule being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, with one completed trial evaluating its bioavailability. The drug is being developed by Pfizer, Inc.
Revatio is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
Revatio is in Phase 1 clinical development. It has one completed trial that enrolled 18 healthy volunteers. The drug is investigational and has not been approved for any indication.
Revatio has one completed clinical trial, NCT01027117, which was a relative bioavailability study of crushed tablets, extemporaneously prepared formulation, and intact tablets at a 20 mg dose in healthy volunteers. The trial was conducted in Belgium.
Revatio is a brand name for sildenafil, a phosphodiesterase type 5 inhibitor. The clinical trial NCT01027117 evaluated the bioavailability of Revatio tablets in healthy volunteers.